We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Immune Dysfunction in Allergic Asthma

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT00189228
First Posted: September 16, 2005
Last Update Posted: October 12, 2017
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Collaborator:
National Heart, Lung, and Blood Institute (NHLBI)
Information provided by (Responsible Party):
Mark Schuyler, University of New Mexico
September 10, 2005
September 16, 2005
October 12, 2017
September 2005
June 2008   (Final data collection date for primary outcome measure)
anti-KLH antibody [ Time Frame: 6 months ]
Asthma and control patients are immunized with KLH
Not Provided
Complete list of historical versions of study NCT00189228 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
Immune Dysfunction in Allergic Asthma
Not a Drug Trial. We Are Using Anti-IgE to Examine the Role of Pulmonary Mast Cells in Asthma
We are using anti-IgE to investigate the role of pulmonary mast cells in asthma.
Subjects with mild allergic asthma are examined before, immediately after and 2 months after a course of treatment with anti-IgE. The following are examined: Allergen skin tests, allergen induced asthma, peripheral blood basophils, pulmonary bronchial mucosal mast cells.
Interventional
Not Provided
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Basic Science
Asthma
Drug: Xolair
Patients are administered Xolair
Experimental: xolair
This is not a drug study examining differences of therapeutic outcomes. It uses Xolair as an intervention that might change the outcome of immunization.
Intervention: Drug: Xolair
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
18
June 2008
June 2008   (Final data collection date for primary outcome measure)

Inclusion Criteria:

Mild asthma, adults -

Exclusion Criteria:

children. on inhaled or systemic steroids

Sexes Eligible for Study: All
18 Years to 45 Years   (Adult)
No
Contact information is only displayed when the study is recruiting subjects
United States
 
 
NCT00189228
UNMSCOR
R01HL044253 ( U.S. NIH Grant/Contract )
Yes
Not Provided
Not Provided
Mark Schuyler, University of New Mexico
University of New Mexico
National Heart, Lung, and Blood Institute (NHLBI)
Study Director: Mark Schuyler, MD UNM HSC
University of New Mexico
January 2013

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP